or Try an Advanced Search...

    Technical Analysis for IMTX - Immatics N.V.

    Grade Last Price % Change Price Change
    F 10.01 2.35% 0.23
    IMTX closed up 2.35 percent on Friday, April 26, 2024, on 67 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 14
    *** please verify all earnings dates ***
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical IMTX trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Multiple of Ten Bullish Other 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    New Downtrend Bearish 2.35%
    Multiple of Ten Bearish Other 2.35%
    Below Lower BB Weakness 2.35%
    Gapped Down Weakness 2.35%
    Lower Bollinger Band Touch Weakness 2.35%
    Older End-of-Day Signals for IMTX ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 2 days ago
    Rose Above Previous Day's High 2 days ago
    60 Minute Opening Range Breakout 2 days ago
    Up 2% 2 days ago
    Up 1% 2 days ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    IMTX Chart by TradingView
    Basic chart:

    Profile

    Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCER™). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Biopharmaceutical Cancer Clinical Medicine Immune System Immunotherapy Cancer Treatment Treatment Of Cancer Cell Therapy Virotherapy Immunotherapies T Cell Adoptive Cell Transfer

    Is IMTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Mar 21 Immatics reports FY results
    Mar 21 Immatics Announces Full Year 2023 Financial Results and Corporate Update
    Mar 15 With 52% institutional ownership, Immatics N.V. (NASDAQ:IMTX) is a favorite amongst the big guns
    Feb 3 Immatics' (NASDAQ:IMTX) investors will be pleased with their notable 35% return over the last year
    Feb 3 Immatics: Pioneering TCR Therapies In The Fight Against Cancer
    Jan 18 Immatics prices upsized stock offering to raise $175 million
    Jan 18 Immatics Announces Pricing of $175 Million Public Offering
    Jan 17 Immatics commences public offering of shares
    Jan 17 Immatics Announces Proposed Public Offering
    Jan 16 DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
    See more IMTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 13.16
    52 Week Low 6.91
    Average Volume 445,298
    200-Day Moving Average 10.86
    50-Day Moving Average 11.35
    20-Day Moving Average 10.49
    10-Day Moving Average 10.20
    Average True Range 0.48
    RSI (14) 37.11
    ADX 25.88
    +DI 10.62
    -DI 21.95
    Chandelier Exit (Long, 3 ATRs) 10.25
    Chandelier Exit (Short, 3 ATRs) 11.11
    Upper Bollinger Bands 11.18
    Lower Bollinger Band 9.81
    Percent B (%b) 0.15
    BandWidth 13.08
    MACD Line -0.36
    MACD Signal Line -0.34
    MACD Histogram -0.0231
    Fundamentals Value
    Market Cap 1.03 Billion
    Num Shares 103 Million
    EPS -1.22
    Price-to-Earnings (P/E) Ratio -8.20
    Price-to-Sales 15.41
    Price-to-Book 4.40
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 10.43
    Resistance 3 (R3) 10.40 10.22 10.36
    Resistance 2 (R2) 10.22 10.12 10.24 10.34
    Resistance 1 (R1) 10.12 10.05 10.17 10.15 10.31
    Pivot Point 9.94 9.94 9.97 9.96 9.94
    Support 1 (S1) 9.84 9.84 9.89 9.87 9.71
    Support 2 (S2) 9.66 9.77 9.68 9.68
    Support 3 (S3) 9.56 9.66 9.66
    Support 4 (S4) 9.59